Keros Therapeutics Inc
NASDAQ:KROS

Watchlist Manager
Keros Therapeutics Inc Logo
Keros Therapeutics Inc
NASDAQ:KROS
Watchlist
Price: 14.3 USD 1.63% Market Closed
Market Cap: 580m USD

Intrinsic Value

KROS's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one KROS stock under the Base Case scenario is 3.16 USD. Compared to the current market price of 14.3 USD, Keros Therapeutics Inc is Overvalued by 78%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

KROS Intrinsic Value
3.16 USD
Overvaluation 78%
Intrinsic Value
Price
Base Case Scenario

Valuation History
Keros Therapeutics Inc

KROS
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for KROS cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Keros Therapeutics Inc
NASDAQ:KROS
US
Biotechnology
Market Cap
579.9m USD
IPO
Apr 8, 2020
US
Biotechnology
Market Cap
579.9m USD
IPO
Apr 8, 2020
Price
$false
EPS
$false
Company Overview
Loading...
Business Segments
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about KROS?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Keros Therapeutics Inc
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Keros Therapeutics Inc

Current Assets 588.9m
Cash & Short-Term Investments 559.9m
Receivables 2.7m
Other Current Assets 26.2m
Non-Current Assets 27m
PP&E 23.5m
Other Non-Current Assets 3.5m
Efficiency

Free Cash Flow Analysis
Keros Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Keros Therapeutics Inc

Revenue
3.6m USD
Operating Expenses
-214.4m USD
Operating Income
-210.8m USD
Other Expenses
23.5m USD
Net Income
-187.4m USD
Fundamental Scores

KROS Profitability Score
Profitability Due Diligence

Keros Therapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Exceptional 1-Year Revenue Growth
ROIC is Increasing
Declining ROE
21/100
Profitability
Score

Keros Therapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

KROS Solvency Score
Solvency Due Diligence

Keros Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Keros Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

KROS Price Targets Summary
Keros Therapeutics Inc

Wall Street analysts forecast KROS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for KROS is 31.62 USD with a low forecast of 15.15 USD and a high forecast of 45.15 USD.

Lowest
Price Target
15.15 USD
6% Upside
Average
Price Target
31.62 USD
121% Upside
Highest
Price Target
45.15 USD
216% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Keros Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for KROS is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

KROS Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one KROS stock?

The intrinsic value of one KROS stock under the Base Case scenario is 3.16 USD.

Is KROS stock undervalued or overvalued?

Compared to the current market price of 14.3 USD, Keros Therapeutics Inc is Overvalued by 78%.

Back to Top